Differential Effects of IL-27 on
I nterleukin-27 is a new heterodimeric cytokine of the IL-12 family that is composed of two chains, EBV-induced gene 3 (EBI3), 4 a 33-kDa glycosylated protein homologous to the p40 subunit of IL-12 (1) , and p28, a 28-kDa peptide analogous to the p35 subunit of IL-12 (2) . In mouse or human primary cultures in vitro, IL-27 was found to be primarily expressed by activated monocytes and monocyte-derived dendritic cells, whereas in human tissues EBI3 and p28 coexpression was predominantly observed in macrophages or macrophage-derived cells and in endothelial cells (2) (3) (4) . IL-27 receptor complex comprises two ␤-chains, IL-27R (also called WSX-1 or TCCR) and gp130 (2, 5) . IL-27 is the only known ligand for IL-27R, whereas gp130 is a receptor component of several cytokines of the IL-6 family. By quantitative RT-PCR, IL-27R and gp130 were found to be coexpressed by a large variety of cells, including monocytes, dendritic cells, T and B lymphocytes, NK cells, mast cells, and endothelial cells (5) , indicating that IL-27 may display pleiotropic functions.
So far, most studies on the role of IL-27 in immunity have focused on its role in the regulation of T cell and inflammatory responses (reviewed in Refs. 6 and 7). Initial studies showed that IL-27 plays an important role in the early development of Th1 responses. Specifically, IL-27 was shown to act on naive CD4 ϩ T cells through activation of the Jak/STAT pathway (8 -11) . In these cells, IL-27 induces expression of the Th1-specific transcription factor, T-bet, and of the ␤2 chain of the IL-12 receptor, thereby conferring responsiveness to IL-12. IL-27 also synergizes with IL-12 for IFN-␥ production by naive CD4 ϩ T cells and induces proliferation of naive but not memory CD4 ϩ T cells (2) . Consistent with these in vitro data, mice deficient for IL-27R showed impaired Th1 responses to intracellular pathogens, Listeria monocytogenes and Leishmania major (12, 13) . Subsequent studies using mouse models showed that IL-27 roles were broader and more complex, and a role for IL-27 both as positive and negative regulator of T cell responses has emerged (14 -23) . Studies with IL-27R Ϫ/Ϫ mice also indicated a role for IL-27R as a negative regulator of innate immunity and of inflammatory responses (15, 19, 22, 24) . In addition, IL-27 was recently shown to act directly on naive CD8
ϩ T cells of mouse spleen by increasing granzyme B expression and subsequent CTL activity (25) , consistent with the antitumoral role of IL-27 and its adjuvant activity on the CTL response observed in various mouse models in vivo (26 -29) . In addition to its direct role on CD4 ϩ and CD8 ϩ T cells, IL-27 also acts directly on monocytes and mast cells, in which it induces gene expression of inflammatory cytokines (5) .
Little is known on the role of IL-27 in the B cell response. In germinal centers (GC) of B cell follicles of secondary lymphoid organs, the naive B cell that has encountered a specific Ag undergoes a succession of events, including proliferation, somatic hypermutation, Ig class switching, apoptosis, or positive selection, leading to terminal differentiation into a plasma cell or a memory B cell with high specificity for the Ag (reviewed in Refs. 30 -32) . This set of events is regulated by cytokines at different steps. A recent study (33) showed that IL-27 induced IgG2a class switching in mouse spleen B cells. No data have been reported on its role on human B cells. In this study, we analyzed the expression profile of both chains of the IL-27 receptor, IL-27R and gp130, on the surface of human tonsillar B cells, and investigated IL-27 effects on total tonsillar B cells and on the three main B cell subsets present in tonsils, i.e., naive, GC, and memory B cells. Our results indicate that IL-27 receptor expression is highly regulated during B cell differentiation and activation and that IL-27 effects vary depending on the stage of B cell differentiation and on the costimulus delivered to the B cell.
Materials and Methods

Isolation of human B cells and B cell subsets
B cells were isolated from human tonsils obtained with informed consent from patients undergoing tonsillectomy at Necker Hospital. Tonsils were grinded and the cell suspension was filtered through gauze. Tonsillar mononuclear cells were then isolated by Ficoll-Paque Plus (Amersham Biosciences) density centrifugation and subjected to CD2 microbead depletion and magnetic separation by using LS columns (Miltenyi Biotec). The resulting B cell preparations were consistently from Ͼ98 to 99.5% CD19 ϩ as assessed by FACS analysis. Naive, GC, and memory B cells were isolated by magnetic separation based on their differential expression levels of two cell surface markers, IgD and CD38 (Fig. 1) . Total B cells were separated into IgD ϩ (naive B cells) and IgD Ϫ populations using antiIgD mAb (mouse IgG2a; BD Biosciences) followed by goat anti-mouse IgG microbeads (Miltenyi Biotec) and magnetic separation by using LS columns (Miltenyi Biotec). IgD Ϫ cells were further separated into IgD Ϫ CD38 Ϫ (memory B cells) and IgD Ϫ CD38 ϩ (GC B cells) by incubation with anti-CD38-FITC mAb (BD Biosciences) followed by anti-FITC microbeads (Miltenyi Biotec) and separation by using LS columns. The negative fraction (memory B cells) was collected and the positive fraction was passed again over a MS column to remove CD38 low cells from the GC B cell fraction. As assessed by FACS analysis, the purity of each isolated B cell subset was Ն95%.
Purified B cells or B cell subsets (2 ϫ 10 6 /ml) were cultured in RMPI 1640 medium supplemented with 10% FBS, L-glutamine, and antibiotics in the presence of goat polyclonal anti-or anti-␥ F(abЈ) 2 (Jackson ImmunoResearch Laboratories), goat polyclonal CD40 Ab (R&D Systems), Staphylococcus aureus Cowan strain (SAC) (Pansorbin, Calbiochem), and recombinant cytokines. rIL-27 corresponding to one-chain EBI3p28 fusion protein (DNAX Research Institute) was used at 50 ng/ml, unless otherwise indicated. IL-12 was purchased from R&D Systems and used at 20 ng/ml. For STAT activation assay, B cells (5 ϫ 10 6 /ml) were incubated in RPMI 1640 medium containing 2% FBS, with or without IL-27 for 15 min at 37°C. The reaction was stopped by diluting cells in cold PBS containing 2% FBS and 0.01% sodium azide.
Cell surface immunofluorescent staining and FACS analysis
Purified total B cells (5 ϫ 10 5 to 1.5 ϫ 10 6 per staining) were saturated in PBS containing 20% normal human serum for 20 min before incubation with specific Abs. All stainings and washes were performed in FACS buffer (PBS containing 2% FBS and 0.01% sodium azide). IL-27R, gp130, and IL-12R␤1 were detected, respectively, with mouse anti-TCCR mAb (clone 191106, IgG2b; R&D Systems), mouse anti-gp130 mAb (clone AN-G30 (34), IgG1, developed in Hugues Gascan's laboratory, Angers, France), and mouse anti-IL-12R␤1 mAb (clone 2.4E6, IgG1; BD Biosciences) at 10 g/ml, in parallel with the isotype control mAbs, MOPC141 (mouse IgG2b; Sigma-Aldrich) and MOPC21 (mouse IgG1; Sigma-Aldrich), followed by PE-conjugated F(abЈ) 2 of goat anti-mouse IgG (Beckman Coulter). IL-12R␤2 was detected with rat anti-IL-12R␤2 mAb (clone 2B6, IgG2a; BD Biosciences) at 10 g/ml in parallel with a rat IgG2a isotype control (R&D Systems), followed by PE-conjugated F(abЈ) 2 of goat anti-rat IgG (Beckman Coulter). PE-labeled cells were then stained simultaneously with anti-CD38-PE-cyanine 5 (PC5) and anti-IgD-FITC mAbs (BD Biosciences) to identify the different B cell subsets. For the detection of cell surface expression of CD10, CD11a, CD23, CD25, CD39, CD40, CD54, CD58, CD80, CD86, CD95, HLA-DR, and HLA class I, total B cells were stained simultaneously with PE-conjugated specific Abs (all from BD Biosciences), along with anti-CD38-PC5 and anti-IgD-FITC Abs. CD19-FITC (Beckman Coulter), CD38-FITC (BD Biosciences), and IgD-FITC (DakoCytomation) Abs were used to verify the purity of total B cell or B cell subset purification. Cells were analyzed on FACScan using CellQuest software. 
Proliferation assay
Western blot analysis and ELISA
Before lysis, cells were washed in ice-cold PBS. For STAT analysis, cells were lysed for 1 h on ice in lysis buffer (1% Nonidet P-40, 50 mM Tris (pH7.4), 150 mM NaCl, 3% glycerol, and 1.5 mM EDTA) containing protease inhibitors (1 mM PMSF, 1 g/ml pepstatin, and 10 g/ml leupeptin) and phosphatase inhibitors (1 mM Na 3 V0 4 and 10 mM NaF). Cell lysate was centrifuged for 15 min at 13,000 ϫ g and the supernatant was assayed for protein concentration using the microBCA protein assay (Pierce).
T-bet expression was analyzed from nuclear extracts. To this end, cells were lysed for 30 min on ice in lysis buffer A (0.1% Nonidet P-40, 10 mM HEPES (pH 7.9), 10 mM KCl, and 1 mM EDTA) containing protease inhibitors as indicated above. Cell lysate was centrifuged for 15 min at 13,000 ϫ g, and the cell pellet was subjected to a second extraction in lysis buffer B (20 mM HEPES (pH 7.9), 1 mM EDTA, 420 mM NaCl, and 10% glycerol) supplemented with protease inhibitors for 1 h on ice. Cell lysate was centrifuged for 15 min at 13,000 ϫ g, and protein concentration of the nuclear extract was determined as indicated above. Lysates were subjected to SDS-PAGE and transferred to nitrocellulose for immunoblotting. Tyrosine-phosphorylated STAT proteins were detected using polyclonal rabbit anti-phospho-STAT1, 2, 3, 5, and 6 Abs (1/1000 dilution; Cell Signaling Technology). STAT1 was detected with rabbit polyclonal Ab (1/1000 dilution; Cell Signaling Technology) and STAT3 was detected with mouse F-2 mAb (2 g/ml; Santa Cruz Technology). T-bet was detected with mouse 4B10 mAb (2 g/ml; Santa Cruz Technology). Binding of mouse or rabbit Abs was detected with HRP-conjugated anti-mouse or HRP-conjugated protein A, respectively (Amersham Biosciences). Peroxidase reaction was developed with chemiluminescence reagents (Pierce).
Levels of IFN-␥ in culture supernatants of stimulated B cells were determined by ELISA using human IFN-␥ Quantikine (detection limit: 15 pg/ml; R&D Systems).
Results
Surface expression of IL-27R and gp130 on human tonsillar B cells
Previous studies (5, 33) on IgD Ϫ CD38 ϩ GC B cells. In contrast, gp130 was expressed at similar low levels in all three B cell subsets. This expression profile was independent of the donor because similar data were observed using B cells from five different donors.
To investigate the effect of CD40 and surface Ig ligation on IL-27R and gp130 expression levels, B cells were stimulated for 1 or 2 days with anti-CD40 or anti-Abs (Fig. 2) . Following CD40 activation, IL-27R and gp130 surface expression was increased on each B cell subset, notably on IgD Ϫ CD38 ϩ GC B cells that, once activated, displayed significant levels of both chains of the IL-27 receptor. This increased expression was already observed after 1 day of stimulation and was more pronounced after 2 days of stimulation ( Fig. 2 and data not shown) . Anti-stimulation resulted in a similar increase of IL-27R and gp130 surface expression on IgD ϩ CD38 Ϫ naive and IgD Ϫ CD38 Ϫ memory B cells. Regarding IgD Ϫ CD38 ϩ GC B cells, no or very low increase of both chains was observed following 1 day of anti-Ab stimulation. After 2 days of anti-stimulation, their number was in most experiments too low to allow their analysis (data not shown). Combination of anti-CD40 and anti-stimulation resulted in expression levels similar to those observed with anti-CD40 Ab alone (data not shown).
Taken together, these data indicate that the expression of IL-27 receptor is highly regulated during B cell differentiation and following B cell activation.
IL-27 activates STAT1 and STAT3 in human tonsillar B cells
To verify that the IL-27 receptor expressed on human tonsillar B cells is functional, we analyzed by Western blot the activation of STAT proteins in response to IL-27 stimulation. As shown on Fig.  3A , incubation of freshly purified total B cells with IL-27 resulted in strong STAT1 and STAT3 tyrosine phosphorylation. No STAT2, STAT5, or STAT6 activation was observed (data not shown).
To determine in which B cell subsets STAT1 and STAT3 are activated, we performed similar experiments using magnetically purified B cell subpopulations (Fig. 3B) . A strong STAT1 and STAT3 phosphorylation was consistently observed in naive B cells. In memory B cells, a significant STAT1 phosphorylation and a weak STAT3 phosphorylation were observed. Despite of a lower total STAT1 protein level and of very low levels of IL-27R and gp130 at the cell surface, a weak phosphorylation of STAT1 and STAT3 was detected in GC B cells. Although we cannot exclude that this weak signal may be in part due to the presence of Ͻ5% contaminating naive B cells, this suggests that the low level of IL-27 receptor expression detected on GC B cells may be sufficient to induce a weak STAT activation. Thus, while STAT1 and STAT3 activation was observed in each B cell subset in response to IL-27, the extent of STAT1 and STAT3 phosphorylation was very variable depending on the B cell subset.
IL-27 induces T-bet expression in anti-CD40 or anti-Ig activated naive and memory B cells
In mouse CD4
ϩ and CD8 ϩ naive T cells, IL-27 induces T-bet expression in a STAT1-dependent manner (11, 25) . To investigate whether IL-27 induces T-bet expression in human tonsillar B cells, total B cells were stimulated for 1 or 2 days with anti-CD40 Ab, alone or in the presence of IL-27, and nuclear extracts were analyzed by immunoblotting for T-bet expression. As shown on Fig.  4A (left panel) , IL-27 increased T-bet expression in CD40-stimulated total B cells. This induction was already maximal after 1 day of stimulation. Similarly, IL-27 induced T-bet expression in total B cells stimulated for 1 day with anti-Ab (Fig. 4A, right panel) .
Because we previously observed a significant STAT1 phosphorylation in naive and memory B cells, we analyzed T-bet induction in these two B cell subsets activated via CD40 or via their surface Ig (anti-Ab for naive B cells and a combination of anti-and anti-␥ Abs for optimal stimulation of memory B cells) (Fig. 4B) . Our results indicated that IL-27 induced significant T-bet expression in anti-CD40-or anti--stimulated naive B cells (Fig. 4B,  lane 3) . Induction of T-bet by IL-27 was also observed in anti-CD40-or anti-Ig-stimulated memory B cells (Fig. 4B, lane 5) . However, T-bet induction in these latter was weaker than the one observed in naive B cells.
T-bet has been involved in IFN-␥ production by different cell types, including murine B cells (35) (36) (37) (38) (39) . In human naive CD4 T cells, IL-27 by itself does not induce detectable IFN-␥ production, but synergizes with IL-12 for its production (2). To investigate whether B cells produce IFN-␥ in response to IL-27, total tonsillar B cells were stimulated for 2-4 days with anti-CD40 or anti-Ig Abs (anti-Ab alone or in combination with anti-␥ Ab), in the absence of recombinant cytokines or in the presence of IL-27 with or without IL-12, and culture supernatants were tested by ELISA for IFN-␥ production (three to four different donors were tested in each condition). In the absence of cytokines or in the presence of IL-27 alone, no IFN-␥ was detected (detection limit: 15 pg/ml). In the presence of both IL-12 and IL-27, IFN-␥ levels either remained undetectable or did not significantly exceed those observed with IL-12 alone (data not shown). Thus, in human B cells, IL-27, alone or in combination with IL-12, had no significant effect on IFN-␥ production.
IL-27 induces IL-12R␤2 surface expression in anti--stimulated naive B cells
Next, we examined whether IL-27-mediated T-bet induction observed in B cells is followed by induction of IL-12R␤2 expression, as it has been demonstrated in mouse and human CD4 ϩ T cells and in mouse CD8
ϩ T cells (8 -10, 25) . In parallel, we analyzed the IL-27 effect on the expression of the ␤1 chain of the IL-12 receptor.
By cell surface staining and FACS analysis, IL-12R␤2 chain was undetectable in freshly isolated tonsillar B cells (Fig. 5A) . Stimulation with either anti-CD40 Ab or anti-Ig Ab (anti-Ab alone or in combination with anti-␥ Ab) failed to induce detectable expression of this chain (Fig. 5A) . In contrast, IL-12R␤1 chain was detected in unstimulated naive, GC, and memory B cells, and its expression increased on each B cell subset following anti-CD40 or anti-Ig stimulation (Fig. 5A) .
When B cells were stimulated for 2 days with anti-CD40 Ab in the presence of IL-27, a weak increase of IL-12R␤1 surface expression was consistently observed on total B cells, compared with B cells stimulated with anti-CD40 Ab alone (Fig. 5B) . This induction was observed on naive B cells and occasionally on memory B cells, but not on GC B cells (data not shown). Similarly, a weak induction of IL-12R␤1 by IL-27 was consistently observed on total and naive B cells stimulated with anti-Ig Abs (anti-Ab or a combination of anti-and anti-␥ Abs). Under these conditions, no or a very weak induction was observed on memory B cells. These data were consistent among the different donors tested (five and six different donors tested for anti-CD40 and anti-Ig stimulation, respectively).
No induction of IL-12R␤2 expression by IL-27 was observed by FACS analysis on total B cells or on B cell subsets stimulated via CD40 (12 different donors tested, Fig. 5B and data not shown) . In contrast, when B cells were stimulated with anti-Ig Abs, a significant induction of IL-12R␤2 expression by IL-27 was observed in most cases (10 of 12 different donors tested). In these cases, IL-12R␤2 induction was observed in naive B cells, but generally not on memory B cells (Fig. 5B) . On both total and naive B cells, induction of IL-12R␤2 expression by IL-27 was heterogeneous, in that only a fraction of cells showed IL-12R␤2 positivity (Fig. 5B) .
Altogether, these data indicated that the pattern of IL-12R␤2 induction by IL-27 did not overlay with that of T-bet induction. Indeed, although induction of T-bet expression by IL-27 was observed in CD40-stimulated B cells, no induction of IL-12R␤2 expression by IL-27 was detected in these cells. In particular, lack of induction of IL-12R␤2 expression was observed using B cells from donors that were tested for T-bet induction and showed significant induction of T-bet expression by IL-27 (B cells from the same donor were used for the experiments shown in Fig. 4A , left panel, and Fig. 5B ). Also, the low level of T-bet induction by IL-27 observed in anti-Ig-stimulated memory B cells was not sufficient to induce detectable induction of IL-12R␤2 expression in this specific B cell subset.
IL-27 induces surface expression of CD54 (ICAM-1), CD95 (Fas), and CD86 (B7.2) on anti-Ig-stimulated naive and memory B cells
In addition to IL-12R␤1 and ␤2, we investigated whether IL-27 could modulate the expression level of various cell surface molecules known to be regulated following B cell activation. Of the various B cell surface molecules analyzed (CD10, CD11a, CD23, CD25, CD39, CD40, CD54, CD58, CD80, CD86, CD95, HLA-DR, and HLA class I) only three of them, CD54, CD86, and CD95, showed consistent variation in their surface expression in the presence of IL-27. Thus, as shown in Fig. 6 , IL-27 increased expression of CD54, CD86, and CD95 on anti--stimulated total B cells. This induction was observed on both naive and memory B cells, although it was weaker on the latter. Induction of CD54 and CD95 expression was already detectable after 1 day of stimulation, whereas induction of CD86 expression was generally detectable only after 2 days of stimulation. Similar induction data were observed when B cells were stimulated with a combination of anti-FIGURE 6. IL-27 up-regulates CD54, CD86, and CD95 surface expression on anti--stimulated naive and memory B cells. Purified B cells were stimulated for 2 days with anti-Abs (10 g/ml) in the absence or presence of IL-27 (50 ng/ml) and were stained with PE-conjugated anti-CD54, anti-CD86, or anti-CD95 Abs, along with anti-IgD-FITC and anti-CD38-PC5 Abs. Staining observed in the absence of IL-27 is represented by a filled gray line, whereas staining observed in the presence of IL-27 is represented by a bold line. x-axis, log fluorescence intensity; y-axis, cell number. Representative data of experiments performed using B cells from six different donors are shown. and anti-␥ Abs (data not shown). However, no or very weak induction of these three molecules by IL-27 was observed in anti-CD40-stimulated B cells (data not shown). Similar data were observed using tonsillar B cells from six different donors.
IL-27 enhances proliferation of activated naive and GC B cells
The effect of IL-27 on B cell proliferation has not been previously investigated. To investigate a possible effect of IL-27 on B cell proliferation, total B cells were incubated for 3 days with suboptimal doses of either anti-CD40 Ab (0.1, 0.25, or 0.5 g/ml) or anti-Ab (2, 5, or 10 g/ml) in the absence or presence of IL-27, and DNA synthesis was assessed by thymidine incorporation. In each condition, addition of IL-27 resulted in increased B cell proliferation (Fig. 7A) . The proliferative effect of IL-27 was modest on CD40-stimulated B cells and more pronounced on anti--stimulated B cells. On average, proliferation of anti-CD40-stimulated B cells increased by Ͼ70% in the presence of IL-27, whereas that of anti--stimulated B cells increased by 400% ( p Ͻ 0.01). No consistent increase was observed in anti-␥-stimulated B cells (data not shown). This proliferative effect of IL-27 was dose dependent. On anti--stimulated B cells, a positive effect of IL-27 was already detectable with 1 ng/ml IL-27, and maximal effects were observed at concentrations ranging from 50 to 100 ng/ml IL-27 ( Fig. 7B and data not shown) .
Next, the proliferative response of the different B cell subsets to IL-27 was analyzed using purified B cell subsets. Because the different B cell subsets responded differently to each stimulus, different suboptimal concentrations of Abs were used to stimulate each B cell subset. We observed a positive effect of IL-27 on proliferation of anti--stimulated naive B cells, as their proliferation increased by Ͼ400% ( p Ͻ 0.01; Fig. 7C ). In our experiments, no significant proliferative response to anti-stimulation alone was observed in GC and memory B cells, and addition of IL-27 had no significant effect (data not shown). When each B cell subset was stimulated with anti-CD40 Ab, proliferation of naive and GC B cells increased by ϳ100 and ϳ50% on average, respectively ( p Ͻ 0.01). In contrast, proliferation of CD40-stimulated memory B cells was not affected by IL-27 (Fig. 7C) . To determine whether the lack of response of memory B cells to IL-27 was specific to the stimulus (anti-CD40 Ab), other B cell stimuli were tested. When memory B cells were stimulated with SAC particles, results were similar to those obtained with anti-CD40 stimulation: addition of IL-27 did not increase memory B cell proliferation, while proliferation of SAC-stimulated naive B cells tested in parallel increased by ϳ70% on average in the presence of IL-27 ( p Ͻ 0.01; Fig. 7D ). Only in anti-␥-stimulated memory B cells was a small but not statistically significant proliferative effect of IL-27 observed (data not shown).
Discussion
This is the first report demonstrating a role of IL-27 on human B cells. With respect to B cells, only one recent study (33) reported IL-27 effects on murine primary spleen B cells. In that former study (33) , the effects of IL-27 were studied on total B cells only. One subunit of the IL-27 receptor complex, IL-27R, was detected at the mRNA level in total murine spleen B cells and was found to be expressed at similar levels in unstimulated or CD40-stimulated B cells. In murine spleen B cells, IL-27 was shown to induce STAT1 activation and IgG2a class switching in a STAT1-dependent but IFN-␥ independent manner. The effect of IL-27 on IL-12 receptor expression, cell proliferation, or expression of B cell activation markers was not investigated (33) .
Our results showed that IL-27 has direct effects on human tonsillar B cells and that the B cell response to IL-27 is regulated at multiple steps. First, surface expression of IL-27 receptor subunits is regulated during B cell differentiation and following B cell activation. Thus, whereas naive and memory B cells displayed constitutive expression of IL-27R and gp130, GC B cells exhibited barely detectable levels of IL-27R. The differential expression of IL-27R by the different B cell subsets is consistent with a previous study (40) , in which gene expression during GC reaction was tracked by gene profiling. In this study, IL-27R gene expression was found to be down-regulated by 32-fold upon differentiation of naive B cells into GC B cells and to be strongly up-regulated (21.5-fold) during the GC to memory B cell transition, to regain expression levels comparable to those observed in naive B cells. In addition, we found that expression of both chains of the IL-27 receptor increased on each B cell subset upon in vitro B cell activation via CD40 or surface Ig. These results are in line with recent findings showing that mitogenic stimulation of murine CD4 ϩ T cells through the TCR enhances IL-27 receptor surface expression (41) .
Second, independently from their levels of IL-27 receptor surface expression, B cell subsets responded differently to IL-27. In most assays used in our study, naive B cells exhibited a stronger response than memory B cells to IL-27, although both subsets expressed comparable levels of IL-27 receptor surface expression. In naive B cells, a strong phosphorylation of both STAT1 and STAT3 was observed, whereas in memory B cells a moderate activation of STAT1 and a low activation of STAT3 were observed. Similar to STAT activation, a weaker induction of T-bet expression by IL-27 was observed in memory B cells than in naive B cells, regardless of the mode of B cell activation (CD40 or Ig stimulation). Also, IL-27-mediated induction of the expression of different surface molecules, such as IL-12R␤1 and ␤2, CD54, CD86, and CD95, was generally more robust on naive B cells than on memory B cells. One striking difference between the two B cell subsets was their proliferative response to IL-27. A previous study (2) showed that IL-27 enhances proliferation of naive, but not memory, CD4 ϩ T cells stimulated by anti-CD3 and anti-CD28 Abs in the presence of anti-IL-2 Ab. In a similar manner, we found that, IL-27 increased proliferation of naive B cells stimulated with anti-CD40 Ab or SAC, but not that of memory B cells. This lack of effect on memory B cells was not due to the lack of a functional IL-27 receptor, because IL-27 induced expression of T-bet and other molecules (CD54, CD86, and CD95) in these cells. In mouse naive CD4 ϩ T cells, IL-27-induced proliferation has been shown to be STAT1 independent, whereas STAT3 was considered to be important for IL-27-induced proliferation (11) . Taken together, these findings suggest that the lower level of STAT3 activation induced by IL-27 in memory B cells compared with naive B cells may be involved in the lack of proliferative effect of IL-27 observed in memory B cells in these conditions.
We showed that IL-27 induced T-bet expression in anti-CD40 or anti-Ig stimulated human tonsillar B cells. In murine B cells, T-bet has been linked to IgG2a class switching. Specifically, T-bet has been shown to be necessary for IgG2a class switching in response to T-independent stimuli such as LPS, but not T-dependent stimuli via CD40 (36, (42) (43) (44) . Consistent with these data and the lower amount of serum IgG2a observed in IL-27R-deficient mice (12), IL-27 was shown to induce IgG2a class switching in a T-bet-dependent manner in LPS-stimulated murine spleen B cells (33) . The role of T-bet in class switching in human B cells is unknown and the observations from murine B cells cannot be transposed to human B cells. First, IgG subclasses differ in humans and mice, and in humans the IgG2a isotype does not exist. Second, due to their very low levels of TLR4 expression, human B cells respond very poorly to LPS stimulation (45) and as a consequence isotype switching cannot be studied in these cells in the context of LPS stimulation. Thus, in human B cells, it was difficult to establish a direct link between T-bet, IL-27, and class switching to a specific isotype. In addition, our preliminary experiments suggest that IL-27 has no major effect on Ig class or IgG subclass production. Indeed, when culture supernatants of CD40-or SAC-activated tonsillar B cells were tested by ELISA for Ig classes (IgM, IgG, IgA, and IgE) or IgG subclasses (IgG1, IgG2, IgG3, and IgG4), no significant and consistent variation was observed when IL-27 was present during the 12-day culture (three to five different donors tested; our unpublished observations). T-bet and IL-27 have also been involved in inhibition of IL-4-mediated IgG1 class switching in murine B cells (33, 36, 42) . However, when we analyzed IgG4 (the human equivalent of the murine IgG1 isotype) production by tonsillar B cells stimulated with anti-CD40 Ab plus IL-4, in the presence or absence of IL-27, no marked inhibiting effect of IL-27 was observed (our unpublished data). Thus, in human B cells, IL-27 does not appear to have a major effect on Ig production and class switching.
Another functional consequence of T-bet induction is the upregulation of IL-12R␤2 chain expression (35, 37) . By FACS analysis, the IL-12R␤2 chain was undetectable in unstimulated B cells and in anti-CD40-or anti-Ig-stimulated B cells, but was induced in naive B cells following stimulation with anti-Ig Ab plus IL-27. In contrast, IL-12R␤1 chain was detected on each B cell subset in the absence of stimulation. Its expression significantly increased following CD40 or surface Ig stimulation, and showed a further increase in the presence of IL-27. In previous studies (46, 47) of IL-12 receptor expression in human tonsillar B cells, expression of both chains was analyzed by RT-PCR. IL-12R␤1 and ␤2 genes were found to be constitutively expressed in each B cell subset. This constitutive expression of IL-12R␤2 gene by unstimulated tonsillar B cells contrasts with the lack of detection of IL-12R␤2 surface expression by FACS analysis. This failure to detect IL-12R␤2 by FACS is more likely to be due to a low sensitivity of the immunostaining technique compared with RT-PCR analysis than to a dissociated expression of IL-12R␤2 mRNA and protein. Indeed, freshly purified tonsillar B cells express a functional IL-12 receptor at the cell surface, as shown by their ability to respond to IL-12 (46) . Also, this low sensitivity of IL-12R␤2 immunostaining may be responsible for the lack of detectable IL-12R␤2 induction in response to anti-plus IL-27 stimulation observed in 2 of the 12 donors tested. Indeed, when IL-12R␤2 expression was analyzed in these two donors at the mRNA level by RT-PCR, a clear induction of IL-12R␤2 mRNA in response to anti-plus IL-27 stimulation was observed. In contrast, in CD40-stimulated B cells, no up-regulation of IL-12R␤2 by IL-27 was observed, both at the protein and mRNA levels ( Fig. 5B and unpublished observations) . This selective induction of IL-12R␤2 expression by IL-27 in anti--, but not anti-CD40-, stimulated B cells, indicates that this IL-27 effect depends on the mode of B cell activation, and that T-bet induction is not sufficient to induce detectable induction of IL-12R␤2 expression in CD40-stimulated B cells.
Similarly, we observed an induction of CD54, CD86, and CD95 expression by IL-27 when B cells were stimulated via their surface Ig, but no or a very low induction when B cells were stimulated via CD40. This much lower IL-27 effect observed in this latter condition may be due to the already strong induction of these molecules by CD40 stimulation itself. Indeed, although both anti-Ig and anti-CD40 Abs induced expression of these molecules, the induction observed following anti-Ig stimulation was much weaker than the one observed following anti-CD40 stimulation (our unpublished observations). Our finding that IL-27 induced ICAM-1 expression on human tonsillar B cells, is in line with a study (48) published while this manuscript was in preparation, that showed induction of ICAM-1 expression by IL-27 in mouse CD4 ϩ T cells. Altogether, these data indicate that IL-27 has multiple effects on B cells and may play a role at different stages of B cell differentiation. Further studies are necessary to delineate the mechanisms underlying the differential response of each B cell subset to IL-27 and to investigate its possible role in B cell pathological conditions.
